These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 29178024

  • 1. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).
    Wu YL, Hirsh V, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O'Byrne K, Geater SL, Zhou C, Massey D, Märten A, Lungershausen J, Yang JC.
    Patient; 2018 Feb; 11(1):131-141. PubMed ID: 29178024
    [Abstract] [Full Text] [Related]

  • 2. Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.
    Kato T, Yoshioka H, Okamoto I, Yokoyama A, Hida T, Seto T, Kiura K, Massey D, Seki Y, Yamamoto N.
    Cancer Sci; 2015 Sep; 106(9):1202-11. PubMed ID: 26094656
    [Abstract] [Full Text] [Related]

  • 3. Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence.
    Ke EE, Wu YL.
    Ther Adv Respir Dis; 2016 Jun; 10(3):256-64. PubMed ID: 26929305
    [Abstract] [Full Text] [Related]

  • 4. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
    Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC.
    J Thorac Oncol; 2016 Mar; 11(3):380-90. PubMed ID: 26823294
    [Abstract] [Full Text] [Related]

  • 5. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
    Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV.
    J Clin Oncol; 2013 Sep 20; 31(27):3342-50. PubMed ID: 23816967
    [Abstract] [Full Text] [Related]

  • 6. Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.
    Felip E, Hirsh V, Popat S, Cobo M, Fülöp A, Dayen C, Trigo JM, Gregg R, Waller CF, Soria JC, Goss GD, Gordon J, Wang B, Palmer M, Ehrnrooth E, Gadgeel SM.
    Clin Lung Cancer; 2018 Jan 20; 19(1):74-83.e11. PubMed ID: 28729180
    [Abstract] [Full Text] [Related]

  • 7. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
    Vidal ÓJ.
    Med Clin (Barc); 2016 Apr 20; 146 Suppl 1():12-8. PubMed ID: 27426243
    [Abstract] [Full Text] [Related]

  • 8. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
    Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM, Miller VA, Palmer M, Yang JC.
    J Thorac Oncol; 2013 Feb 20; 8(2):229-37. PubMed ID: 23328549
    [Abstract] [Full Text] [Related]

  • 9. Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer.
    Geater SL, Xu CR, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Palmer M, Shi Y, Lungershausen J, Wu YL.
    J Thorac Oncol; 2015 Jun 20; 10(6):883-9. PubMed ID: 25933111
    [Abstract] [Full Text] [Related]

  • 10. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
    Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, Shi Y, Lee DH, Laskin J, Kim DW, Laurie SA, Kölbeck K, Fan J, Dodd N, Märten A, Park K.
    Ann Oncol; 2017 Feb 01; 28(2):270-277. PubMed ID: 28426106
    [Abstract] [Full Text] [Related]

  • 11. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
    Brückl W, Tufman A, Huber RM.
    Expert Rev Anticancer Ther; 2017 Feb 01; 17(2):143-155. PubMed ID: 27898252
    [Abstract] [Full Text] [Related]

  • 12. Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.
    Watanabe S, Inoue A, Nukiwa T, Kobayashi K.
    Anticancer Res; 2015 Dec 01; 35(12):6957-61. PubMed ID: 26637922
    [Abstract] [Full Text] [Related]

  • 13. Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution.
    Koyama N, Watanabe Y, Iwai Y, Kawamura R, Miwa C, Nagai Y, Hagiwara K, Koyama S.
    Chemotherapy; 2017 Dec 01; 62(3):151-158. PubMed ID: 28110331
    [Abstract] [Full Text] [Related]

  • 14. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
    Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL.
    Lancet Oncol; 2015 Jul 01; 16(7):830-8. PubMed ID: 26051236
    [Abstract] [Full Text] [Related]

  • 15. Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
    Reguart N, Remon J.
    Future Oncol; 2015 Jul 01; 11(8):1245-57. PubMed ID: 25629371
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
    Sárosi V, Balikó Z.
    Magy Onkol; 2014 Dec 01; 58(4):325-9. PubMed ID: 25517450
    [Abstract] [Full Text] [Related]

  • 18. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L.
    Value Health; 2015 Sep 01; 18(6):774-82. PubMed ID: 26409604
    [Abstract] [Full Text] [Related]

  • 19. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
    Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV.
    Lancet Oncol; 2015 Feb 01; 16(2):141-51. PubMed ID: 25589191
    [Abstract] [Full Text] [Related]

  • 20. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa S, Saka H, Kubo A, Kawaguchi T, Takada M, Rosell R, Kurata T, Ou SH.
    Oncologist; 2015 Mar 01; 20(3):307-15. PubMed ID: 25657199
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.